ArticleMediterranean journal of rheumatology2026
Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes.
Article in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic and Therapeutic Challenge: VEXAS Syndrome with Multisystem Inflammation and Myelodysplasia: A Case Report.Mediterranean journal of rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This review aimed to synthesise current literature on the clinical presentation, renal pathology, treatment, and outcomes of kidney involvement in VEXAS syndrome. Methods: We conducted a systematic review in accordance with PRISMA guidelines, including all original English-language publications from 2020 to May 14, 2025, that described any form of renal involvement in VEXAS syndrome. Data extracted included patient demographics, clinical presentation, renal biopsy findings, treatment strategies (including dialysis), clinical outcomes, and cause of death. Results: We included nine studies (five case series, three case reports, and one retrospective cohort), providing a total of 39 individual patient records. The reported frequency of renal involvement in VEXAS syndrome ranged from 3.6% to as high as 39% at 10-year follow-up. All documented cases involved male patients. The most common clinical presentations included acute kidney injury (AKI), chronic kidney disease (CKD), proteinuria, and haematuria. Among biopsy findings, interstitial nephritis was most frequently reported, followed by glomerulonephritis, minimal change disease, acute tubular injury, and IgA nephropathy. Less frequently, membranous nephropathy, peritubular capillaritis, glomerulosclerosis, and light chain cast nephropathy were also observed. Treatment primarily involved glucocorticoids, with steroid-sparing agents added based on the presence of coexisting non-renal manifestations. Renal outcomes were generally favourable, with most patients achieving recovery and only rare instances of dialysis dependence. The contribution of renal involvement to overall mortality remains unclear. Conclusion: Renal manifestations in VEXAS syndrome are varied but remain underexplored due to the rarity of the disease. Focused studies on kidney involvement are crucial to improve our understanding of the underlying pathophysiology and its clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.